Perrigo Past Earnings Performance

Past criteria checks 0/6

Perrigo's earnings have been declining at an average annual rate of -57%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been declining at an average rate of 3.5% per year.

Key information

-57.0%

Earnings growth rate

-56.8%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate-3.5%
Return on equity-2.7%
Net Margin-2.9%
Next Earnings Update09 May 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Perrigo makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BMV:PRGO N Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 224,452-1311,161123
01 Oct 224,401-861,126121
02 Jul 224,344-881,129119
02 Apr 224,203-1351,108120
31 Dec 214,139-1311,108122
02 Oct 214,087-2151,146125
03 Jul 214,047-1351,126128
03 Apr 214,015-111,105125
31 Dec 204,088441,100122
26 Sep 204,358771,096148
27 Jun 204,5461431,109162
28 Mar 204,7461401,147175
31 Dec 193,8701591,095119
28 Sep 194,7102471,157173
29 Jun 194,652871,142172
30 Mar 194,6891141,127220
31 Dec 184,7321311,124219
29 Sep 184,8201231,133221
30 Jun 184,9182351,158216
31 Mar 184,9691291,158166
31 Dec 174,9461201,146168
30 Sep 174,994-1,3131,161162
01 Jul 175,025-2,9471,154174
01 Apr 175,127-3,4121,177179
31 Dec 165,281-4,0131,206184
01 Oct 165,308-2,8721,241189
02 Jul 165,320-1,0211,289180

Quality Earnings: PRGO N is currently unprofitable.

Growing Profit Margin: PRGO N is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PRGO N is unprofitable, and losses have increased over the past 5 years at a rate of 57% per year.

Accelerating Growth: Unable to compare PRGO N's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRGO N is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.1%).


Return on Equity

High ROE: PRGO N has a negative Return on Equity (-2.7%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/28 20:44
End of Day Share Price 2023/01/29 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Perrigo Company plc is covered by 38 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Ishan MajumdarBaptista Research
Douglas TsaoBarclays